Literature DB >> 8047826

Symptoms and disease severity in gastro-oesophageal reflux disease.

J P Galmiche1, S Bruley des Varannes.   

Abstract

The definition of criteria relevant to disease severity assessments should be considered in parallel with the long-term aims of treatment in gastro-oesophageal reflux disease (GORD). There is no doubt that the resolution of symptoms is the major management aim. Heartburn and regurgitation are specific for GORD when they are the predominant symptoms, but prove to be insensitive when the diagnosis of GORD is based on the measurement of oesophageal acid exposure. A relationship between the frequency of heartburn and the degree of acid exposure has been reported in GORD patients both with and without oesophagitis. GORD may also, however, cause a wide spectrum of atypical symptoms (e.g. non-cardiac chest pain or respiratory symptoms). To the extent that a causal relationship between these symptoms and reflux episodes has been established, evaluation of symptom severity should also encompass these atypical presentations. The role of symptoms in the prediction of relapse of oesophagitis is controversial, but in several studies the presence of residual symptoms of GORD at the time of healing has indicated a greater probability of relapse. Endoscopy is a useful technique for the evaluation of disease severity. Indeed, even typical symptoms may not predict the presence and severity of oesophagitis in an individual patient. Despite the fact that the interpretation of therapeutic trials is often impeded by differences in the grading systems used, healing rates of oesophageal lesions are inversely proportional to the initial severity of oesophagitis when drugs such as H2-receptor antagonists are used. Differences are less evident with highly effective drugs such as omeprazole.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 8047826     DOI: 10.3109/00365529409105366

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  12 in total

Review 1.  Gastro-oesophageal reflux disease and Helicobacter pylori: an intricate relation.

Authors:  D McNamara; C O'Morain
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

Review 2.  Diagnosis of reflux disease.

Authors:  N I McDougall
Journal:  Ir J Med Sci       Date:  1996 Jul-Sep       Impact factor: 1.568

Review 3.  Treatment of gastro-oesophageal reflux disease in adults.

Authors:  J P Galmiche; E Letessier; C Scarpignato
Journal:  BMJ       Date:  1998-06-06

4.  Effects of prior endoluminal gastroplication on subsequent laparoscopic Nissen fundoplication.

Authors:  B Tierney; A Iqbal; M Haider; C Filipi
Journal:  Surg Endosc       Date:  2007-01-06       Impact factor: 4.584

Review 5.  Lansoprazole for maintenance of remission of erosive oesophagitis.

Authors:  James W Freston; Robert L Jackson; Bidan Huang; E David Ballard
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 6.  Trends in the management of gastro-oesophageal reflux disease.

Authors:  J M Lee; C A O'Morain
Journal:  Postgrad Med J       Date:  1998-03       Impact factor: 2.401

7.  Identifying patients with gastroesophageal reflux disease: validation of a practical screening tool.

Authors:  Joshua J Ofman; Michael Shaw; Kay Sadik; Amy Grogg; Kirsten Emery; Jay Lee; Eileen Reyes; Steven Fullerton
Journal:  Dig Dis Sci       Date:  2002-08       Impact factor: 3.199

8.  Diagnosis and management of non-erosive reflux disease--the Vevey NERD Consensus Group.

Authors:  I M Modlin; R H Hunt; P Malfertheiner; P Moayyedi; E M Quigley; G N J Tytgat; J Tack; R C Heading; G Holtman; S F Moss
Journal:  Digestion       Date:  2009-06-17       Impact factor: 3.216

9.  Gastroesophageal reflux disease: medical or surgical treatment?

Authors:  Theodore Liakakos; George Karamanolis; Paul Patapis; Evangelos P Misiakos
Journal:  Gastroenterol Res Pract       Date:  2009-12-31       Impact factor: 2.260

10.  Prospective Acid Reflux Study of Iran (PARSI): methodology and study design.

Authors:  Siavosh Nasseri-Moghaddam; Hadi Razjouyan; Seyed Maysam Alimohamadi; Mansoureh Mamarabadi; Mohamad-Hamed Ghotbi; Pardis Mostajabi; Amir-Ali Sohrabpour; Masoud Sotoudeh; Behnoush Abedi; Azadeh Mofid; Mehdi Nouraie; Shahnaz Tofangchiha; Reza Malekzadeh
Journal:  BMC Gastroenterol       Date:  2007-11-20       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.